IMPROVED SURVIVAL IN CHILDREN WITH GRAFT VERSUS HOST DISEASE WHO RESPOND TO MESOBLAST'S CELL THERAPY
February 15, 2015 18:33 ET
|
Mesoblast
NEW YORK CITY and MELBOURNE, Australia, Feb. 15, 2015 (GLOBE NEWSWIRE) -- Results of 160 pediatric patients treated with Mesoblast's proprietary allogeneic Tier 1 product candidate MSC-100-IV for...
Mesoblast Partner JCR Pharmaceuticals Files for Marketing Approval of the First Allogeneic Stem Cell Product in Japan
September 30, 2014 20:17 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Sept. 30, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today reported that its Japanese partner, JCR...